BioNexus Gene Lab Corp.
$1.51 -$0.03 (-1.95%) 1D Market openKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 24
From its Feb 2 high, the share price fell 47%.
Peak close $2.83 on Feb 2; trough close $1.51 on Jul 24. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -47% -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jun 15
The stock moved +16.8% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jun 15 -
Feb 5
The stock moved -15.3% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Feb 5
The story updates itself as events post · The wolf reports; you decide
Snapshot
About BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific).
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.